Beam Therapeuticsの株式の価格
Beam Therapeuticsの株式の価格 は何ですか。
Beam Therapeutics Inc.の株式の価格 は9.14です。
株式の価格 の定義は何ですか。
1株当たりキャッシュは、会社の手持ち現金を会社の発行済株式で割ったものです。
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
NASDAQのセクタHealth Careにおける株式の価格 の企業と比べるBeam Therapeutics
Beam Therapeuticsは何をしますか。
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeuticsと類似の株式の価格
- Edenred SAの株式の価格 は9.11です。
- Sopra Steria SAの株式の価格 は9.12です。
- BILL Incの株式の価格 は9.12です。
- Bhansali Engineering Polymersの株式の価格 は9.13です。
- Bajaj Electricalsの株式の価格 は9.14です。
- Zhongliangの株式の価格 は9.14です。
- Beam Therapeuticsの株式の価格 は9.14です。
- Prime Focusの株式の価格 は9.14です。
- Hang Seng Bankの株式の価格 は9.14です。
- Kubotaの株式の価格 は9.15です。
- The South India Paper Millsの株式の価格 は9.15です。
- ITOCHUの株式の価格 は9.16です。
- IQVIA Incの株式の価格 は9.17です。